Duchenne Muscular Dystrophy With Confirmed Genetic Mutation Therapeutics
1. Duvyzat patent expiration
Treatment: A method for the treatment of duchenne muscular dystrophy (dmd) using givinostat
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7329689 | ITALFARMACO SPA | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
Jan, 2026
(6 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421184 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(6 years from now) | |
| US9867799 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(6 years from now) | |
| US10688047 | ITALFARMACO SPA | Physically and chemically stable oral suspensions of givinostat |
Oct, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2029 |
| Orphan Drug Exclusivity(ODE-473) | Mar 21, 2031 |
Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient
NCE-1 date: 21 March, 2028
Market Authorisation Date: 21 March, 2024
Dosage: SUSPENSION
More Information on Dosage
DUVYZAT family patents
